Cover Image
市場調查報告書

腎纖維化: 開發中產品分析

Kidney Fibrosis - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 251573
出版日期 內容資訊 英文 134 Pages
訂單完成後即時交付
價格
Back to Top
腎纖維化: 開發中產品分析 Kidney Fibrosis - Pipeline Review, H1 2018
出版日期: 2018年04月24日 內容資訊: 英文 134 Pages
簡介

在腎臟中積蓄細胞外基質的話,會引起腎纖維化。這是以腎小球硬化症和尿細管間質性纖維化為特徵的進行性的疾病,對腎臟功能有害。 原因有外傷,感染疾病,手術,環境要素,以及化學物質和放射線的暴露。 症狀有疼痛,排尿相關問題,噁心嘔吐等。 以藥物和腎臟移植管理症狀。

本報告提供腎纖維化的治療藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關開發的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等最新的新聞和發表。

腎纖維化概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;各企業
  • 開發中產品;各大學/機關
  • 企業開發中的產品
  • 在大學/機關研究中的產品

治療藥的評估

  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • AbbVie Inc
  • Allergan Plc
  • Angion Biomedica Corp
  • Apollo Endosurgery Inc
  • BiOrion Technologies BV
  • Cellmid Ltd
  • Epigen Biosciences Inc
  • Evotec AG
  • Galectin Therapeutics Inc
  • GenKyoTex SA
  • Horizon Pharma Plc
  • Intercept Pharmaceuticals Inc
  • Isarna Therapeutics GmbH
  • MorphoSys AG
  • Pharmaxis Ltd
  • ProMetic Life Sciences Inc
  • Regulus Therapeutics Inc
  • Sirnaomics Inc
  • Symic Biomedical Inc
  • Vascular Biogenics Ltd

藥物簡介

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC10384IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Fibrosis - Pipeline Review, H1 2018, provides an overview of the Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline landscape.

Accumulation of extracellular matrix in the kidney causes kidney fibrosis. It is a progressive disorder characterized by glomerulosclerosis and tubulointerstitial fibrosis and may lead to detrimental effects on the kidney functioning. Predisposing factors are trauma, injury, infections, surgery, environmental factors and exposure to chemicals or radiation. Symptoms include pain, problems related to urination, nausea and vomiting. The condition may be managed with medication and kidney transplant.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kidney Fibrosis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Kidney Fibrosis and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 27 and 7 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 6 molecules, respectively.

Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Fibrosis (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Kidney Fibrosis - Overview
    • Kidney Fibrosis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Kidney Fibrosis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Kidney Fibrosis - Companies Involved in Therapeutics Development
    • AdAlta Ltd
    • Angion Biomedica Corp
    • BiOrion Technologies BV
    • Cellmid Ltd
    • Epigen Biosciences Inc
    • Evotec AG
    • Galectin Therapeutics Inc
    • Genzyme Corp
    • Isarna Therapeutics GmbH
    • Les Laboratoires Servier SAS
    • Pharmaxis Ltd
    • ProMetic Life Sciences Inc
    • Redx Pharma Plc
    • Regulus Therapeutics Inc
    • Sirnaomics Inc
    • Symic Biomedical Inc
    • Vascular Biogenics Ltd
  • Kidney Fibrosis - Drug Profiles
    • 1D-11 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AD-214 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ANG-3070 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ANG-3586 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ANG-4201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMP-7 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BOT-191 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CAB-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CT-140 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs for Tissue Fibrosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fluorofenidone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Smad7 for Hypertensive Cardiomyopathy and Kidney Fibrosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GRMD-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IP-9 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ISTH-0047 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LJ-1888 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • melittin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MSB-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MSB-014 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oligonucleotides to Inhibit MIR199a for Fibrosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • P-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PAT-1251 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PAT-505 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PBI-4050 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PXS-4820 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PXS-5033A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PXS-5338K - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PXS-5382A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • REDX-06109 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RG-012 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SB-300 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Insulin-Regulated AminoPeptidase for Alzheimer's Disease, Cardiac and Renal Fibrosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Integrin for Kidney Fibrosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize LPA1 Receptor for Metastatic Breast Cancer and Renal Fibrosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Cyclophilin D for Obesity and Renal Fibrosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • STP-705 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Agonize AGTR2 for Kidney Fibrosis, Liver Fibrosis and Myocardial Fibrosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Agonize BMP7 Receptor for Renal Fibrosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TEW-7197 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VB-0004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VB-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VB-4P5 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VB-703 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Wnt-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Kidney Fibrosis - Dormant Projects
  • Kidney Fibrosis - Discontinued Products
  • Kidney Fibrosis - Product Development Milestones
    • Featured News & Press Releases
      • Nov 13, 2017: AdAlta to present at Anti-Fibrotic Drug Development Summit in Boston
      • Sep 06, 2017: Pharmaxis Announces Anti Fibrotic LOXL2 Program Clears Preclinical Development And Set To Commence Phase 1 Trials
      • Sep 04, 2017: AdAlta to present kidney fibrosis data at Australian and New Zealand Society of Nephrology Annual Scientific Meeting
      • Apr 25, 2017: Galectin Therapeutics Receives Notice of Japanese Decision to Grant a Composition of Matter Patent for GR-MD-02
      • Nov 18, 2016: ProMetic presents PBI-4050's positive effect on diabetic patients' kidneys at the American Society of Nephrology Annual Meeting
      • Jul 12, 2016: Galectin Therapeutics Receives Notice of Australian Patent to be Granted for the Use of GR-MD-02 in Liver, Kidney, Lung or Heart Fibrosis
      • Nov 12, 2015: Regulus Announces Grant of Patent Covering Lead microRNA Therapeutics
      • Nov 09, 2015: ProMetic's PBI-4050 data on renal fibrosis and pancreatic function featured at the American Society of Nephrology's annual meeting
      • Oct 29, 2015: ProMetic's PBI-4050 Cleared to Commence Clinical Trial in Patients With Type 2 Diabetes and Multi-Organ Fibrosis in Europe
      • Oct 05, 2015: Regulus to Present Additional Preclinical Data Supporting RG-012 as a Novel microRNA Therapeutic in Development for Alport Syndrome at ASN's Kidney Week 2015
      • Aug 13, 2015: Galectin Therapeutics Receives U.S. Patent Notice of Allowance for Use of Pectin Compounds to Reduce Fibrosis in Multiple Diseases
      • Oct 14, 2014: Regulus Therapeutics To Present New Preclinical Data on Multiple Programs At 10th Annual Oligonucleotide Therapeutics Society Meeting
      • Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter
      • Jul 25, 2014: Galectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Kidney Fibrosis, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Kidney Fibrosis - Pipeline by AdAlta Ltd, H1 2018
  • Kidney Fibrosis - Pipeline by Angion Biomedica Corp, H1 2018
  • Kidney Fibrosis - Pipeline by BiOrion Technologies BV, H1 2018
  • Kidney Fibrosis - Pipeline by Cellmid Ltd, H1 2018
  • Kidney Fibrosis - Pipeline by Epigen Biosciences Inc, H1 2018
  • Kidney Fibrosis - Pipeline by Evotec AG, H1 2018
  • Kidney Fibrosis - Pipeline by Galectin Therapeutics Inc, H1 2018
  • Kidney Fibrosis - Pipeline by Genzyme Corp, H1 2018
  • Kidney Fibrosis - Pipeline by Isarna Therapeutics GmbH, H1 2018
  • Kidney Fibrosis - Pipeline by Les Laboratoires Servier SAS, H1 2018
  • Kidney Fibrosis - Pipeline by Pharmaxis Ltd, H1 2018
  • Kidney Fibrosis - Pipeline by ProMetic Life Sciences Inc, H1 2018
  • Kidney Fibrosis - Pipeline by Redx Pharma Plc, H1 2018
  • Kidney Fibrosis - Pipeline by Regulus Therapeutics Inc, H1 2018
  • Kidney Fibrosis - Pipeline by Sirnaomics Inc, H1 2018
  • Kidney Fibrosis - Pipeline by Symic Biomedical Inc, H1 2018
  • Kidney Fibrosis - Pipeline by Vascular Biogenics Ltd, H1 2018
  • Kidney Fibrosis - Dormant Projects, H1 2018
  • Kidney Fibrosis - Dormant Projects, H1 2018 (Contd..1), H1 2018
  • Kidney Fibrosis - Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development for Kidney Fibrosis, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products by Top 10 Targets, H1 2018
  • Number of Products by Stage and Top 10 Targets, H1 2018
  • Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Top 10 Routes of Administration, H1 2018
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2018
  • Number of Products by Top 10 Molecule Types, H1 2018
  • Number of Products by Stage and Top 10 Molecule Types, H1 2018
Back to Top